News & Updates
Filter by Specialty:
Biologic DMARDs offer clinical benefits in adult-onset Still disease
15 May 2024
byStephen Padilla
Use of biologic disease-modifying antirheumatic drugs (bDMARDs), particularly tocilizumab (TCZ), anakinra (ANK), and canakinumab (CNK), appears safe and effective in the treatment of adult-onset Still disease (AOSD), results of a systematic review and meta-analysis have shown.
Biologic DMARDs offer clinical benefits in adult-onset Still disease
15 May 2024Perceptions of SLE flare differ between patients, physicians
15 May 2024
Patients differ from physicians regarding their views of systemic lupus erythematosus (SLE) flares, a study has found. The former see flares as days of having fatigue, pain, and skin issues, while the latter define flares as periods of elevated clinical SLE activity.
Perceptions of SLE flare differ between patients, physicians
15 May 2024Uniform threshold to rule out MI works well in male, female patients
14 May 2024
A uniform cardiac troponin threshold to identify myocardial infarction (MI) risk demonstrates safety and efficacy in both male and female patients, reports a study.